<code id='B89EAEDDD8'></code><style id='B89EAEDDD8'></style>
    • <acronym id='B89EAEDDD8'></acronym>
      <center id='B89EAEDDD8'><center id='B89EAEDDD8'><tfoot id='B89EAEDDD8'></tfoot></center><abbr id='B89EAEDDD8'><dir id='B89EAEDDD8'><tfoot id='B89EAEDDD8'></tfoot><noframes id='B89EAEDDD8'>

    • <optgroup id='B89EAEDDD8'><strike id='B89EAEDDD8'><sup id='B89EAEDDD8'></sup></strike><code id='B89EAEDDD8'></code></optgroup>
        1. <b id='B89EAEDDD8'><label id='B89EAEDDD8'><select id='B89EAEDDD8'><dt id='B89EAEDDD8'><span id='B89EAEDDD8'></span></dt></select></label></b><u id='B89EAEDDD8'></u>
          <i id='B89EAEDDD8'><strike id='B89EAEDDD8'><tt id='B89EAEDDD8'><pre id='B89EAEDDD8'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:4
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images

          Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

          Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

          advertisement

          Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          As digital health tech proliferates, a new institute aims to cut through hype
          As digital health tech proliferates, a new institute aims to cut through hype

          AdobeAnew$50millionnonprofitinitiativeaimstoindependentlyevaluatehealthtechnologies’impactoncostsand

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Group opposing PBM reform sets lobbying record

          Aconservativegroupadvocatingagainstchanginghowpharmacymiddlemenoperatespentmorethan$1milliononlobbyi